Graphite Bio, Inc. (GRPH): Price and Financial Metrics
GRPH Price/Volume Stats
| Current price | $22.26 | 52-week high | $22.62 |
| Prev. close | $3.27 | 52-week low | $2.01 |
| Day low | $21.35 | Volume | 46,900 |
| Day high | $22.62 | Avg. volume | 282,405 |
| 50-day MA | $3.03 | Dividend yield | N/A |
| 200-day MA | $2.62 | Market Cap | 1.30B |
GRPH Stock Price Chart Interactive Chart >
Graphite Bio, Inc. (GRPH) Company Bio
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Latest GRPH News From Around the Web
Below are the latest news stories about GRAPHITE BIO INC that investors may wish to consider to help them evaluate GRPH as an investment opportunity.
What Makes Graphite Bio, Inc. (GRPH) a New Buy StockGraphite Bio, Inc. (GRPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
LENZ Therapeutics and Graphite Bio Announce Merger AgreementSAN DIEGO & SOUTH SAN FRANCISCO, Calif., November 15, 2023--LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ: GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia, the inevitable loss of near vision that impacts the daily lives of |
We're Keeping An Eye On Graphite Bio's (NASDAQ:GRPH) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Graphite Bio Announces Departure of Chief Financial OfficerSOUTH SAN FRANCISCO, Calif., June 23, 2023--Graphite Bio, Inc. (Nasdaq: GRPH) today announced that Alethia Young, the Company’s Chief Financial Officer, will step down from her position to pursue other opportunities. Ms. Young will remain with the Company through June 30, 2023 to oversee her current responsibilities and ensure an orderly transition. |
Graphite Bio, Inc.'s (NASDAQ:GRPH) largest shareholders are private equity firms with 43% ownership, institutions own 22%Key Insights Significant control over Graphite Bio by private equity firms implies that the general public has more... |
GRPH Price Returns
| 1-mo | N/A |
| 3-mo | 8.16% |
| 6-mo | 35.32% |
| 1-year | 3.92% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 21.37% |
| 2023 | -21.08% |
| 2022 | -73.29% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...